Laura Deming announces $58M raise for cryopreservation startup Intel Labs, targeting organ transplants first

Summary

Laura Deming, founder of Intel Labs, announced a $58 million raise on September 22, 2025, with $52 million in the current round and approximately $6 million in prior SAFEs. Investors include Lux Capital and Field Ventures. The company is building reversible cryopreservation technology, targeting the organ transplant market as its first commercial application before pursuing whole-body human hibernation.

The Core Science

The fundamental challenge is not simply cold storage — it is avoiding ice formation during the cooling process. Ice crystals expand and rupture tissue, so Intel Labs works to replace organ fluids with chemical formulations that vitrify, turning to glass rather than ice, when cooled rapidly through what Deming calls the "danger zone." Below minus 130 degrees Celsius, molecular movement effectively stops and biological time is paused indefinitely — a principle already demonstrated by IVF embryos cryopreserved for over 30 years and successfully brought to term.

The scientific foundation is not speculative. Researchers at the University of Minnesota have already demonstrated fully reversible cryopreservation of mouse kidneys — the organ is removed, frozen, rewarmed, and transplanted into a mouse without the other kidney, with full survival. Intel Labs is now working to scale that protocol to human-organ size, where thermal mass makes rapid cooling significantly harder.

The Transplant Market Problem

The near-term commercial target is a system in acute need of disruption. Most transplantable organs have a shelf life of four to twelve hours, with some reaching 24 to 36 hours. Donors die unpredictably, forcing surgeons to charter last-minute private planes, operate through the night, and requiring transplant patients to remain within a two-hour radius of their hospital for months or longer, on-call at all times.

Blade, the medical air transport company, built a business of several hundred million dollars in revenue primarily off organ logistics. Deming's argument is that extended, reliable cryopreservation collapses that dependency — organs could ship via standard freight, surgeries could be scheduled rather than emergency-performed, and the 100,000 patients currently on transplant waiting lists, plus millions more who lack access entirely, could see meaningfully better outcomes.

Build Strategy and Milestones

Intel Labs operates as a fully integrated deep tech company, developing chemical formulations, cooling systems, and rewarming systems in-house. Deming frames iteration speed as the primary competitive variable — preclinical protocols can be tested on full human-sized organs on a weekly basis, an unusually fast cycle for biological research. The company recently moved into a large laboratory and is actively hiring engineers, molecular biologists, chemists, and notably neuroscientists, the latter a signal of broader research directions not yet disclosed.

The immediate milestone with the new capital is getting organ preservation products into clinical use. FDA engagement is expected to follow a medical device designation pathway, though the agency classification is not yet confirmed.

Longer-Term Vision

Deming's stated long-term objective is human hibernation — enabling terminal patients to pause biological time while awaiting therapies not yet available. She cites a direct example: her co-founder's father-in-law missed eligibility for a critical mesothelioma clinical trial by months. A second personal example involves a metastatic melanoma patient whose prognosis shifted from six to nine months to ten-plus years simply by being diagnosed in 2015 rather than 2014, underscoring the life-or-death stakes of timing in oncology.

The scaling roadmap tracks organism size: embryos (hundreds of cells), then worms (thousands of cells), then rat kidneys, then human-scale organs, with whole-body human cryopreservation as a distant but explicit endpoint. Space travel is also cited as a downstream application, with Deming noting that human deep-space missions likely require cryo alongside AI and advanced propulsion.

Broader Longevity Context

Deming highlighted the FDA's recent acceptance of lifespan extension as a valid efficacy endpoint for the first time, specifically for Loyal, a longevity drug company targeting dogs. She described this as a significant regulatory inflection point for the longevity field, as the FDA has historically not recognized lifespan extension as a labeling claim for any drug.